Search
Lung Cancer Paid Clinical Trials in California
A listing of 247 Lung Cancer clinical trials in California actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
241 - 247 of 247
The state of California currently has 247 active clinical trials seeking participants for Lung Cancer research studies. These trials are conducted in various cities, including Los Angeles, San Francisco, San Diego and Sacramento.
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Trial
COVID Vaccine Age 50-64 Study (Up to $710 Total Compensation)
Recruiting
Multiple COVID-19 investigational vaccine studies are now enrolling participants (Age 50-64), with appointments available. Participants who qualify may receive up to $710 in total compensation.
If eligible, participants may be matched to one of the current COVID-19 vaccine studies. Should you express interest, the study team will contact you directly to provide further details and answer any questions about study procedures, time commitment, potential risks/benefits, and compensation.
If eligible, participants may be matched to one of the current COVID-19 vaccine studies. Should you express interest, the study team will contact you directly to provide further details and answer any questions about study procedures, time commitment, potential risks/benefits, and compensation.
Conditions:
COVID Vaccine (Age 50-64)
COVID
COVID-19
COVID19
COVID 19
Featured Trial
Vaccine (18+) Clinical Study
Recruiting
We are seeking healthy individuals aged 18 and above who are interested in participating in a vaccine clinical trial.
Conditions:
Vaccine (18+)
Healthy
Healthy Individuals
Healthy Volunteers
Healthy Subjects
Featured Trial
Vaccine (65+) Clinical Study
Recruiting
We are seeking healthy participants aged 65 and above who are interested in participating in a vaccine clinical trial.
Conditions:
Vaccine (65+)
Healthy
Older Adults
Seniors
Healthy Volunteers
Featured Trial
Adult Vaccine Clinical Trial
Recruiting
Looking to boost your immunity?
You may be interested in participating in an Adult Vaccine Clinical Trial.
The Adult Vaccine Research Studies are looking for adults to evaluate the effectiveness of a potential vaccine.
You may be interested in participating in an Adult Vaccine Clinical Trial.
The Adult Vaccine Research Studies are looking for adults to evaluate the effectiveness of a potential vaccine.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Offer
Lose 20% of Body Weight With GLP-1's
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to tirzepatide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Recruiting
This clinical study is an open-label, Phase 1, dose-escalation study to determine the safety, tolerability, and efficacy of the drug product produced by Administering CRX100 alone and in combination with Pembrolizumab in advanced solid malignancies. Patients will be screened and evaluated to determine whether or not they meet stated inclusion criteria. Enrolled subjects will undergo leukapheresis to enable the ex vivo generation of CRX100. Patients with non-small cell lung cancer (NSCLC), ovaria... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/07/2024
Locations: UC San Diego Moores Cancer Center, La Jolla, California +1 locations
Conditions: Solid Tumor, Adult, Triple Negative Breast Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Osteosarcoma, Epithelial Ovarian Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Malignant Melanoma
LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)
Recruiting
This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/27/2023
Locations: University of California, Davis, Sacramento, California
Conditions: Non-small Cell Lung Cancer, Oligoprogressive, Small-cell Lung Cancer
Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer
Recruiting
This is a pilot study using \[18F\]F AraG PET imaging to evaluate the immunological response to checkpoint inhibitor therapy (CkIT) in patients with advanced NSCLC tumors at multiple study sites. The main objectives of the study are to quantify the change in \[18F\]F AraG PET signal before and after CkIT therapy, and to correlate this change in \[18F\]F AraG PET signal with a radiographic response.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/27/2023
Locations: Palo Alto Veterans Institute of Research, Palo Alto, California +1 locations
Conditions: Non Small Cell Lung Cancer
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
Recruiting
A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS or EGFR mutations to determine the maximum tolerated dose and recommended Phase II dose of HBI-2376 and characterize its pharmacokinetic profile.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/12/2023
Locations: City of Hope, Duarte, California +5 locations
Conditions: Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Cancer, Cancer of Pancreas, Cancer of Colon
A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation
Recruiting
A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS G12C mutation to determine the maximum tolerated dose and recommended Phase II dose of HBI-2438 and characterize its pharmacokinetic profile.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/12/2023
Locations: California Cancer Associates for Research and Excellence, Inc. (cCare), Encinitas, California +8 locations
Conditions: Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Cancer of Pancreas, Colon Cancer, Solid Tumor, Cancer
MRI and Biomarkers for Lung Nodules Detected During Lung Cancer Screening
Recruiting
The primary objective of this pilot observational study is to evaluate the accrual and retention rate of a study population from a centralized lung cancer screening program to support MRI and blood-based biomarker research for lung cancer screening.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
08/28/2023
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Lung Cancer
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Recruiting
The goal of this clinical trial is to test the safety and efficacy of KVA12123 alone or combined with pembrolizumab in patients with advanced solid tumors. The main questions this study aims to answer are:
1. What is the safety of KVA12123 when administered alone and in combination with pembrolizumab to advanced cancer patients?
2. What is an appropriate dose of KVA12123 to administer alone and in combination with pembrolizumab to advanced cancer patients in future clinical trials?
Participant... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2023
Locations: UCLA Health (Santa Monica Cancer Care), Santa Monica, California
Conditions: Cancer, Solid Tumor, Melanoma, Carcinoma, Sarcoma, Lung Cancer, Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Uterine Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Thyroid Cancer, Ovarian Cancer, Kidney Cancer, Head and Neck Cancer
241 - 247 of 247
